"For many companies, a successful corporate development strategy should not only encompass in-licensing and R&D collaboration opportunities, but should also take out-licensing and spin-out options into account. Hear from business development executives from large pharma and biotech
companies about how they've made the most of out-licensing technologies and tech platforms, intellectual property and products or product candidates that no longer fit within the companies' portfolios."

Objective1: Prepare for the main risks and challenges presented by emerging markets.

Objective2: Understand actionable best practices and insights to help build organizational capabilities and improve deal processes.

Objective3: Learn from other industries what contributes to success and failure in emerging markets transactions.